Zymeworks company info

What does Zymeworks do?
Zymeworks (NYSE:ZYME) is a biotherapeutics company focused on the development and commercialization of next-generation multifunctional biotherapeutics, designed to improve patient outcomes in cancer and autoimmune diseases. The company is versatile in its approach, engaging in the discovery, development, and commercialization of innovative protein-based therapeutics. Zymeworks' projects center around its proprietary platforms which enhance the efficacy and safety of therapeutic antibodies and antibody-drug conjugates. A key objective for Zymeworks is to advance its pipeline of preclinical and clinical candidates, with the ultimate goal of delivering groundbreaking treatments to patients in need.
Zymeworks  company media
Company Snapshot

Is Zymeworks a public or private company?

key
Ownership
Public

How many people does Zymeworks employ?

people
Employees
282

What sector is Zymeworks in?

pie chart
Sector
Health Care

Where is the head office for Zymeworks ?

location pin
Head Office
Vancouver, Canada

What year was Zymeworks founded?

founded flag
Year Founded
2003
What does Zymeworks specialise in?
/Biopharmaceutical Development /Cancer Therapies /Antibody Therapeutics /Protein Therapeutics /Drug Discovery /Clinical Trials

What are the products and/or services of Zymeworks ?

Overview of Zymeworks offerings
Zymeworks' lead product, zanidatamab, is a bispecific antibody targeting HER2 for various cancers.
The company developed ZW49, a bispecific antibody-drug conjugate for treating HER2-expressing cancers.
ZYME-83 is a preclinical project aimed at addressing solid tumors through innovative molecular targeting.
The Azymetric platform enables the development of bispecific and multispecific antibodies for diverse therapeutic applications.
Zymeworks' Effector Function Enhancement and Control Technology (EFECT) portfolio facilitates the modulation of immune cell interactions.
Their Immune Modulating Drug Conjugates (IMDCs) technology is designed to enhance the delivery and efficacy of immunotherapies.

Who is in the executive team of Zymeworks ?

Zymeworks leadership team
  • Mr. Kenneth H. Galbraith C.A.
    Mr. Kenneth H. Galbraith C.A.
    CEO & Chairman of the Board
  • Dr. Paul  Moore Ph.D.
    Dr. Paul Moore Ph.D.
    Chief Scientific Officer
  • Mr. Mark  Hollywood
    Mr. Mark Hollywood
    Executive VP and Head of Technical & Manufacturing Operations
  • Mr. Daniel  Dex J.D., Ph.D.
    Mr. Daniel Dex J.D., Ph.D.
    Senior VP, Corporate Secretary & General Counsel
  • Diana  Papove
    Diana Papove
    Senior Manager of Corporate Communications
  • Dr. Lindsey  Foulkes B.Sc., Ph.D.
    Dr. Lindsey Foulkes B.Sc., Ph.D.
    Vice President of Corporate Development
  • Ms. Laura  O'Connor
    Ms. Laura O'Connor
    Vice President of Human Resources & DEI
  • Dr. Jeffrey  Smith M.D.
    Dr. Jeffrey Smith M.D.
    Executive VP & Chief Medical Officer